One To Watch

Spore.Bio

A Paris-based biotech/deeptech company developing rapid microbiology testing for industrial quality control. Its deployment model is factory-based, aimed at on-site use in manufacturing environments.

Founding and History

Spore.Bio was founded in 2023. The company has grown quickly through venture financing, including a pre-seed round announced in late 2023 and a Series A announced in February 2025 to industrialize and scale deployments.

Therapy Areas and Focus

Spore.Bio is not a therapeutics developer. It focuses on microbiological quality control and contamination detection for regulated and high-risk manufacturing sectors, including:

Food and beverage production
Biopharma manufacturing (including time-sensitive products where delays in sterility testing are operationally costly)
Cosmetics and personal care manufacturing

Technology Platforms and Modalities

Spore.Bio is building an AI-driven rapid microbiology testing system intended to reduce test turnaround from days to minutes. The company describes a hardware-plus-software approach, combining optical/photonic measurement with machine-learning models to detect and quantify bacterial contamination directly at or near the production line. The value proposition is faster release decisions, earlier deviation detection, and reduced reliance on off-site laboratory workflows.

Strategic Partnerships

Spore.Bio’s operating model is deployment- and validation-led, centered on installing systems in partner factories and supporting method validation for regulated quality environments. The company has also described academic collaboration as part of its R&D approach.

FAQ Section

Spore.Bio develops rapid microbiology testing systems for industrial quality control. The platform combines on-site measurement hardware with AI models to detect and quantify bacterial contamination faster than traditional culture-based methods.

The company targets manufacturing sectors where microbiology testing is routine and time-critical—primarily food, pharmaceuticals, and cosmetics—focused on in-process monitoring and quality release support.

Spore.Bio’s is product-led rather than clinical. The company is scaling its factory-deployed rapid testing system and expanding validation packages and use cases across different manufacturing environments and organism/risk profiles.

January 2026: Spore.Bio was named a recipient of Google.org’s AI for Science funding and announced the launch of Spore.Labs, an AI-native research unit. The company also announced the appointment of Dr Michael J. Miller as VP of Scientific and Regulatory Affairs, aligned to microbiology method validation and contamination control needs in regulated industries.

Company communications emphasize prototype validation work, factory pilots, and the objective of reducing time-to-result versus conventional microbiology. For regulated industries, the key validation threshold is method equivalence and robustness under real manufacturing conditions.

Near-term milestones are commercialization and scale: broader factory deployments, expansion of validated applications, and repeatable quality/regulatory packages that support adoption in pharma-grade environments.

Spore.Bio positions its approach as on-site and AI-enabled, with an emphasis on speed and operational integration into manufacturing workflows—aimed at shifting microbiology from a post-process lab step to a real-time quality control capability.

Want to Update your Company's Profile?